Shots:

• In the August Edition of the Know Your Investor series, we bring a condensed yet illuminating report on Arch Venture Partners 
• In 2023, Arch Ventures Partners participated in 6 investment rounds and added 27 companies focusing on biopharma and manufacturing & services to its portfolio
• For a detailed report on all the investments, reach out to us at connect@pharmashots.com

Established in 1986, Arch Venture Partners invests in science-based companies. The company is headquartered in Chicago, Illinois, United States, with offices in Seattle, San Francisco, and Dublin.

Arch Venture funds companies as low as $50K to hundreds of millions. In Biopharma, the company invests in technologies like antibodies, artificial intelligence (AI) / machine learning (ML), biologic, cell therapy, diagnostic, digital health, DNA, gene editing/CRISPR, gene therapy, genomics, immunotherapy, protein, RNA and small molecule.

In 2023, Arch Venture mainly invested in Series A, Series B, and Series C rounds, followed by Seed, convertible notes, and two private investments. In Biopharma, the company invested in technologies like antibodies, artificial intelligence (AI) / machine learning (ML), biologic, cell therapy, diagnostic, digital health, DNA, gene editing/CRISPR, gene therapy, genomics, high throughput screening, immunotherapy, protein, RNA and small molecule. Illumina, Alnylam Pharmaceuticals, Juno Therapeutics, Vir Biotechnology, and Bluebird Bio, among others, became a part of Arch Venture’s portfolio companies. In 2023, Generate Biomedicines received the highest funding, worth $273M.     

In 2023, Arch Venture made 27 investments. Many of these investments were made to biopharmaceutical companies, manufacturing, and service providers with a focus on Oncology, Autoimmune & Inflammation, Cardiovascular, Infectious, Hematologic, and Neurologic. In 2023, 48.1% of Arch Venture’s total investments were made under Series A, whereas 25.9% accounted for Series B. Arch Venture’s top 3 investments for 2023 are as follows:     

• Series C funding worth $273M to Generate Biomedicines
• Series A funding worth $270M to Orbital Therapeutics Inc.
• Series A funding worth $203M to Paradigm Health Inc.

In 2023, Arch Venture made:

• 9 investments in Q1
• 7 investments in Q2
• 9 investments in Q3
• 2 investments in Q4

The following table represents the top 5 out of the 27 investments made by Arch Venture

Note: (For a complete report, reach out to us at connect@pharmashots.com with the subject line

"Arch Venture Partners" or for early access to complete data for future reports and analysis register here: https://forms.office.com/r/VwFu6aUm80)

Related Post: Know Your Investor: Invus (July’24 Edition) Investments in 2023.